Morningside Venture Invests In Series A Round In US Gene Therapy Company

Login to View

Apic Bio, Inc., an American gene therapy company for treatment of rare genetic diseases, has raised US$40 million, led by Chinese early-stage venture capital group Morningside Venture Investments, according to a January 7 announcement.

Continue reading with a China Money Network subscription

Join Now

Already have an account or paid subscription? Log in